XFOR

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Wednesday reported a loss of $20.2 million in its first quarter. On a per-share basis, the Boston-based company said it had a loss of 16 cents. The company posted revenue of $2.7 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XFOR at https://www.zacks.com/ap/XFOR

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway through 2028 - BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update. “Our top priority remains the execution and full enrollment of the pivotal 4WARD Phase 3 trial of mavorixafor in chronic neutropenia,” said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. “We remain on track to complete enrollment by the end of the third quarter of this year. In addition, we are pleased that the European Commission granted marketing authorization for XOLREMDI® (mavorixafor) for the treatment of patients with WHIM syndrome in the European Union, reinforcing the broader potential of our program to advance therapies for individuals affected by rare hematologic disorders. We look forward to a smooth transfer of the marketing authorization application to our European partner, Norgine, later this year as they proceed with commercialization plans throughout Europe.” Recent Accomplishments and Updates Continued to advance enrollment in the global 4WARD Phase 3 trial of oral, once-daily mavorixafor (with or without G-CSF) in patients with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia, supported by several targeted initiatives: Expanded to over 110 active clinical trial sites worldwide, including more than 20 in the U.S., enhancing enrollment and regulatory alignment; Increased global Medical Affairs engagement including the implementation of a dedicated patient referral pathway for physicians; and, Leveraging data-driven approaches including database mining to identify potential participants. The European Commission granted marketing authorization for XOLREMDI® (mavorixafor) for the treatment of patients with WHIM syndrome in the European Union (EU). The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). European commercialization will be led by X4 Pha...

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for the Treatment of WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway through 2028 - BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. “Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with rare blood diseases,” said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. “We have sharpened our operational focus and implemented targeted initiatives to drive continued progress in 4WARD with enrollment on track for completion in the third quarter of this year. Additionally, we were pleased to receive the positive opinion from the European Medicines Agency recommending the potential European approval of mavorixafor in WHIM syndrome, which would be the first and only therapy in Europe to treat this devastating condition.” Recent Accomplishments and Updates Deployed a series of proactive measures to increase enrollment in the global 4WARD Phase 3 trial of oral, once-daily mavorixafor (with or without G-CSF) in patients with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia, including: Expanding the number of current active clinical trial sites to over 100, including approximately 20 in the U.S.; Enhancing our global Medical Affairs activities to increase Medical Science Liaison (MSL) field engagement and site interaction to educate physicians on our 4WARD trial and mavorixafor’s potential in treating chronic neutropenia; Establishing a patient referral pathway for physicians to assist them in finding trial sites for their chronic neutropenia patients; and Investing in database mining to identify potential participants. European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization of mavorixafor the treatment of WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome in the Europ...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $23.9 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 22 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 36 cents per share. The company posted revenue of $2.6 million in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $1.7 million. For the year, the company reported a loss of $79.2 million, or $1.87 per share. Revenue was reported as $35.1 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XFOR at https://www.zacks.com/ap/XFOR

Vericel Corporation (VCEL) came out with quarterly earnings of $0.45 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +0.74%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced earnings of $0.1, delivering a surprise of +600%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Vericel, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $92.92 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.83%. This compares to year-ago revenues of $75.38 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Vericel shares have added about 3% since the beginning of the year versus the S&P 500's gain of 1.5%. While Vericel has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Vericel was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It...

Company’s strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial Previously announced workforce reductions resulted in $13M annualized cost savings Successful completion of two financial transactions totaling $240.3M; cash runway now extends to the end of 2028 BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today reported financial results for the third quarter ended September 30, 2025 and provided a corporate update. “The third quarter of 2025 was a time of corporate restructuring at X4 with the start of a new leadership team and a renewed focus on chronic neutropenia,” said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. “With a strengthened financial position through two successful financings totaling $240.3 million, our primary focus is now on the completion of the 4WARD Phase 3 pivotal trial of mavorixafor in patients with moderate and severe chronic neutropenia, which has a potential addressable market of 15,000 patients in the US. With a cash runway to the end of 2028, we are now positioned to unlock mavorixafor’s full potential and to establish X4 as a world-class rare hematology company.” Recent Accomplishments and Updates Since early August, the Company has initiated a number of measures to restructure its operations: A shift in the primary focus of the Company to the successful completion of the 4WARD Phase 3 pivotal trial of mavorixafor in patients with moderate and severe chronic neutropenia. A deprioritization of the commercialization of mavorixafor (XOLREMDI) for patients with WHIM syndrome, while maintaining patient access. A 50% reduction in the workforce (expected to generate approximately $13 million in annualized cost savings) with continued cost cutting measures. An increase in the enrollment target for the pivotal Phase 3 4WARD study to 176 patients with enrollment now expected to be completed in third quarter of 2026. The promotion of John Volpone to the role of Chief Operating Officer, in addition to his responsibilities as President. Dr. Adam Craig expanded his role to include oversight of clinical development activities. Since August, the Company raised $240.3 million in gross proceeds from two successful financings: the closing of a $155.3 million underwri...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Wednesday reported a loss of $29.8 million in its third quarter. The Boston-based company said it had a loss of 69 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 79 cents per share. The company posted revenue of $1.8 million in the period, which did not meet Street forecasts. Four analysts surveyed by Zacks expected $1.9 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XFOR at https://www.zacks.com/ap/XFOR

Explore X4 Pharmaceuticals's Fair Values from the Community and select yours Revenue: US$1.97m (up 250% from 2Q 2024). Net loss: US$25.7m (down by 128% from US$90.8m profit in 2Q 2024). US$3.47 loss per share (down from US$13.60 profit in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Looking ahead, revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 5.7% from a week ago. Be aware that X4 Pharmaceuticals is showing 4 warning signs in our investment analysis and 2 of those are a bit unpleasant... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Friday reported a loss of $25.7 million in its second quarter. On a per-share basis, the Boston-based company said it had a loss of $3.47. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $4.53 per share. The company posted revenue of $2 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $1.6 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XFOR at https://www.zacks.com/ap/XFOR

Release Date: May 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. X4 Pharmaceuticals Inc (NASDAQ:XFOR) has made significant progress in the development of Maverick 4 for chronic neutropenia, with over 90% of global trial sites activated. The company has received a notice of allowance from the US Patent Office for Maverick 4, with the patent expected to expire in March 2041. X4 Pharmaceuticals Inc (NASDAQ:XFOR) reported cumulative sales of $3.5 million for Zoremby since its launch, indicating growing demand. The company has secured international partnerships to expand the reach of Maverick 4 in Europe, Australia, New Zealand, and the MENA region. X4 Pharmaceuticals Inc (NASDAQ:XFOR) ended the first quarter of 2025 with nearly $90 million in cash, providing financial stability into the first half of 2026. Sales for the first quarter were slightly lower than the previous quarter due to fluctuations in inventory resupply. The company is still in the early stages of commercialization for Zoremby, with some sales volatility expected. X4 Pharmaceuticals Inc (NASDAQ:XFOR) had significant R&D and SG&A expenses, totaling $18.5 million and $15 million respectively for the first quarter. The company had to implement a 1 for 30 reverse stock split to address NASDAQ listing rule deficiencies. There is a high unmet need in the chronic neutropenia market, with approximately 15,000 individuals in the US still experiencing health challenges despite available treatments. Warning! GuruFocus has detected 4 Warning Signs with XFOR. Q: Can you provide insights into the types of patients being enrolled in the Forward trial and how this aligns with the commercial market? A: (Chief Medical Officer, Dr. Christoph Arbut Engels) The study has specific criteria, and the patient profile is promising. Many principal investigators (PIs) are eager to include more patients, indicating a high demand. The patient profile aligns well with the commercial market, showing a clear interest in enrolling patients with chronic neutropenia. Q: Are the 50,000 diagnosed chronic neutropenia (CN) patients and the 15,000 with high unmet needs figures specific to the US or worldwide? A: (CEO, Dr. Paula Reagan) These figures are specific to the US, based on ICD-10 code analysis and US claims data. Q: What is the target population for the label of Ma...

4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at 8:30 am ET BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2025, and highlighted key recent events and expected upcoming milestones. “The first quarter of 2025 was an extremely productive and value-adding period for X4,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. “Not only did we make significant progress in activating sites and enrolling participants in our ongoing mavorixafor Phase 3 trial in chronic neutropenia, but we also continued to support U.S. commercialization of XOLREMDI (mavorixafor) in WHIM syndrome, while also significantly expanding our global potential following acceptance of our EU regulatory submission in WHIM and the announcement of two international commercialization partnerships. We look forward to continuing to deliver on our milestones in the coming year toward our goal of maximizing the potential of mavorixafor to benefit patients with rare immunodeficiencies.” Key First-Quarter 2025 and Recent Corporate Highlights Advancing Mavorixafor in Chronic Neutropenia (CN) 4WARD Trial Updates. X4 continues to enroll participants in its ongoing global, pivotal Phase 3 clinical trial (NCT06056297), evaluating oral, once-daily mavorixafor in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. As previously reported, an amendment to the 4WARD protocol has been implemented, focusing enrollment on those with the highest unmet needs and refining the definition of ANC response, making it consistent across all trial participants. Overall, the trial seeks to demonstrate statistically significant increases in ANC response and corresponding decreases in annualized infection rate between those on mavorixafor versus placebo. To date, the demographics of the enrolled population are balanced and representative of the targeted...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Thursday reported first-quarter earnings of $282,000. On a per-share basis, the Boston-based company said it had profit of 4 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $4.13 per share. The company posted revenue of $28.8 million in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $9 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XFOR at https://www.zacks.com/ap/XFOR